NASDAQ: BSGM - News and a Bounce?

[View online]( [UNSUBSCRIBE]( NEW MOMENTUM STOCK: NASDAQ: BSGM Today's Alert just had a big drop... That could mean an even BIGGER SQUEEZE!  Did you see the news they just announced? Check it out:  BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology  BioSig Technologies, Inc. Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology Clinical investigations conducted by Cleveland Clinic could expand clinical parameters of BioSig’s digital signal processing technology for arrhythmia care  [BioSig Technologies, Inc.]( (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that it will sponsor a research agreement with Cleveland Clinic Foundation (CCF) to investigate expanded clinical applications for the intracardiac signals acquired by its PURE EP™ System.  Under the terms of the research agreement, Cleveland Clinic will conduct physician initiated scientific research investigating PURE EP™’s potential to address common limitations of signal processing and signal use expansion during— but not limited to— electrophysiology ablation procedures. Results from this research could elucidate new clinical workflow methods impacting the ablation process for numerous arrhythmia types.  The Company has selected Cleveland Clinic, a leading medical center of excellence, based on their world-class physician faculty, research competency, and mutual interest in leveraging digital signal processing technology to further advance the field of cardiac electrophysiology.  “As a non-profit, research, education, and healthcare institution, Cleveland Clinic has a long legacy of innovation in cardiovascular disease, and specifically in the field of electrophysiology. At BioSig, we embody their commitment to clinical discovery and ensuring that optimal treatments are made available to patients with efficiency and efficacy,” said Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. “We are honored to align ourselves with Cleveland Clinic’s expertise as we discover new ways to positively impact procedural workflows by leveraging digital signal processing technology.” BioSig’s PURE EP™ System is currently under evaluation at both Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular & Thoracic Institute. Link to full press:   Previous email incase you missed it below: BSGM is an Emerging Healthcare Company that Could Keep Your Portfolio from Needing a Checkup…  Greetings Investors,   Healthcare is one of the largest and most complex sectors and it has had investors’ attention for years.  There’s a good reason why this year many blue-chip healthcare stocks have been solid gainers in a bear market on both the NASDAQ and the S&P 500 exchanges.  Healthcare is a necessity and companies in this arena often hold up well during tumultuous times. They are looked at as stable companies with offerings and services that people need even if there is a recession. [Solita Marcelli]( the chief investment officer of the Americas at UBS Global Wealth Management, has noted that since 2003, global healthcare stocks have tended to outperform the broader market by more than 6% at times.  During volatile times, healthcare companies that have a “defensive bent” may be the best to keep on your radar.   This includes a quietly trading NASDAQ company called BioSig Technologies, Inc. (NASDAQ: BSGM) which is now advancing the national commercial rollout of its PURE EP™ System.    []( BioSig Technologies, Inc. NASDAQ: BSGM   The PURE EP™ System is BSGM’s first product and it is already FDA 510(k) cleared as a non-invasive class II device!    The system provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.    As an integral part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute, the system has been getting remarkable praise.    In a [blinded clinical study]( recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating.    This bodes well for BSGM, as the global EP market is projected to reach [$16B in 2028]( with an 11.2% growth rate.    Trading at pennies, BioSig Technologies, Inc. (NASDAQ: BSGM) has technology aimed to help prevent a major health crisis, saving significant costs for both patients and the healthcare system. All this is a win-win for healthcare, the company, and potentially shareholders too.    An Unmatched Perspective in Bioelectronic Medicine That Ensures Anything of Potential Significance Never Gets Overlooked!   About the Company   BioSig Technologies (NASDAQ: BSGM) is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.   Many investors are on a quest to find companies that are focused on the biggest trends in healthcare and exhibit major growth potential.    This includes the bioelectronic medicine space, which is a rapidly growing segment of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases.  The company offers an unmatched perspective in bioelectronic medicine that ensures anything of potential significance never gets overlooked.   The space, which includes familiar devices such as pacemakers, is expected to [exceed a staggering $60 billion market by 2029!](   BioSig Technologies, Inc. (NASDAQ: BSGM) is targeting the [anticipated $15.7B electrophysiology (EP) market]( and is seeking to serve a vital market with a device that could be a game changer.   The company is on a solid path to commercial growth and orders are coming in as the company publishes impressive clinical results, expands its product pipeline, and grows internationally.    More on the PURE EP™ System   The PURE EP system is BSGM’s first product and is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.   The patented PURE EP™ System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal dynamic range.   This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution A/D converter. In addition, the PURE EP™ System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency (RF) signal (e.g., from ablation) noise suppression. There is no need for gain switching in this architecture, and the full range of input signals is digitized with high resolution.   The US Patent Office had allowed a [utility patent covering its PURE EP™ noise-filtering technology.](   The recently allowed patent application number 17/091,357 entitled “Universal Notch Filter" was filed on November 6, 2020. The patent describes and claims computer-implemented methods for filtering noise from an input signal.   “We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias.”  -  Kenneth L. Londoner, Chairman, and CEO   More Applications   BSGM is also working with leading experts and organizations to develop additional features of PURE EP™ and explore signal processing applications in disease areas beyond arrhythmia.   In 2017, the company signed a 10-year strategic collaboration with experts at the world renown Mayo Clinic to jointly develop their signal processing technology. These experts see the potential for BSGM's technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology.   A National Commercial Launch Campaign   Under the leadership of its Chief Commercial Officer Gray Fleming, BSGM has implemented several important initiatives to accelerate the transition from its limited market release to a national launch of its PURE EP(TM) System.   The Company currently has over 30 qualified leads and commenced its commercial kick-off back in July.   BSGM also recently doubled the size of its sales organization, with plans of tripling it before the fourth quarter of this year!   The Company appointed a new team of [National Account ExecutivesÂ]( will be strategically located throughout the U.S. to support and accelerate sales growth and adoption of the PURE EP™ System.   ORDERS ARE IN This is one of the most exciting times for the company as orders are now coming in. BSGM recently said the company has been seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System in the coming months.   Since the national commercial launch of its PURE EP™ System in July, the Company’s commercial pipeline has experienced a steady increase in advanced leads and technology adoption across several key regions and centers of excellence.   To date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP(TM) System!   Earlier this month the company announced that [San Antonio Methodist Hospital]( has acquired the PURE EP™ System.   The acquisition, one of many in the pipeline, reaffirms the continued expansion of BioSig’s U.S. footprint and customer base.    THE BOTTOM LINE   Everybody needs healthcare -- or will at some point. And when there’s something everyone needs, there’s a huge opportunity for investors…. Not to mention that this arena is often described as recession-proof.   There’s a good reason why insiders are loading up on BSGM shares. Orders are piling up, there’s a 10-year strategic agreement with the world-famous Mayo Clinic and other big developments!   If everything already mentioned hasn’t intrigued you enough, here are more headwinds to consider. These are the headwinds that are catalysts to propelling medical device stocks to the moon.   Over 79 million baby boomers are getting older and living longer, and that means they require more services such as treatments for ailing hearts, along with the other privileges of aging. In addition, cardiac care is becoming a key strategic area of interest for mergers and acquisitions.   Total medical devices industry M&A deals worth $320.6m were announced globally in [March 2022]( led by [Fresenius Kabi]( ’s $240m acquisition of [Ivenix]( , according to GlobalData’s deals database.   Remember... it says a lot when insiders (including the CEO) are buying shares of their own company! Insiders in the Company have been loading up on shares in August which can be seen in BSGM’s [SEC filings](.. It’s well known that while insiders will sell for many reasons, they buy because they believe their company’s shareholder value will increase.   BSGM has also not long ago appointed [John Siekchaus]( as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories [NYSE: ABT]! AND…. BULLISH ratings are piling up with NASDAQ.com even having [a $4 price target on shares!](   BSGM’s solution is equivalent if not superior to conventional systems and has the potential to diagnose and treat MANY diseases! This could be the beginning of a remarkable future ahead for a company that currently trades at well under $1.00.  Start your research right away! Copyright 2022 © MomentumStocks.io is 50% owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@MomentumStocks.io This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to MomentumStocks.io (MS). MS is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “MS” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BSGM. We have been currently compensated up Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Legends Media Inc for a 1 Day Marketing Program regarding BSGM with a start date of 10/24/2022 to 10/24/2022, We have been previously compensated up Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Legends Media Inc for a 2 Day Marketing Program regarding BSGM with a start date of 10/06/2022 to 10/07/2022. We have been previously compensated Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Open Market Media Group Inc for a 2 Day Marketing Program regarding BSGM with a start date of 6/22/2022 to 6/23/2022. We have been previously compensated Ten Thousand Dollars Cash ($10,000) via bank wire transfer from a third-party Legends Media Inc for a 1 Day Marketing Program regarding BSGM on 8/29/22. MS’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MS often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. , 26 Downing Street, Newark, NJ 07105, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](